India, Sept. 24 -- The following biotech stocks were in focus on September 24, 2026, following notable stock moves and company-specific developments involving clinical programs, regulatory progress, financing and technology platforms.
Apimeds Pharmaceuticals US (APUS)
Apimeds Pharmaceuticals US is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapy for pain and inflammation associated with knee osteoarthritis.
The company's stock surged more than 130% on Thursday, although no specific company-related news was cited for the sharp move.
The company plans to pursue a second Phase 3 trial in the U.S. for Apitox as a potential treatment for knee osteoarthritis in patients who ha...